Mosaic Therapeutics Taps Thomas Fuchs as CEO

Mosaic Therapeutics Ltd, an oncology therapeutics company, has appointed Thomas Fuchs as CEO. Fuchs will lead the company to advance its pipeline of proprietary drug combination programs into the clinic, and through a planned Series B financing round.

“We are delighted to welcome Thomas to Mosaic,” said Edward Hodgkin, Chair of Mosaic’s Board of Directors. “He brings a wealth of oncology therapeutic development and commercialization expertise to Mosaic, alongside a proven track record of building high-performing teams. Thomas’s leadership will enable us to execute on our ambitious plans to cement our position as a leader in synergistic precision oncology and advance our pipeline of proprietary drug combination programs.”

Experience

Fuchs has over 25 years’ experience in leadership positions across early drug development, commercialization and life cycle management, serving in senior oncology biopharma leadership roles in both oncology-focused biotech and big pharma. He was most recently CEO at Cimeio Therapeutics, where he led the early company build backed by a $50M series A financing raise and secured a significant strategic collaboration agreement with Kyowa Kirin.

Previously he spent 15 years at Roche-Genentech, serving in senior leadership roles across the Global Hematology franchise. As Global Franchise Head, he oversaw development strategy, life cycle management and commercialization of Roche-Genentech’s hematology portfolio, covering five marketed products with over $8Bn sales, and a range of development-stage assets.

“Mosaic has built a uniquely differentiated pipeline of drug combination programs with huge potential to bring significant therapeutic benefit to cancer patients,” Fuchs remarked. “I am excited to be joining at this critical juncture. I look forward to working with the leadership team to drive the ongoing fundraising and advance the development of Mosaic’s pipeline into the clinic.”

Fuchs holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science in Business Administration from the University of Wisconsin-Stout.